Gastroesophageal Junction (GEJ) Tumors: Diagnosis, Multimodality Therapy, and Surgical Management

Tumors arising at the gastroesophageal junction (GEJ) occupy the transition between the distal esophagus and proximal stomach. Management requires careful integration of tumor biology, anatomic classification, and coordinated multimodality therapy.

Because GEJ tumors straddle two organ systems, treatment decisions often involve determining whether the disease behaves more like esophageal cancer or gastric cancer, which directly influences systemic therapy strategy and surgical approach.

Care is delivered through a multidisciplinary program integrating surgical oncology, medical oncology, radiation oncology, gastroenterology, radiology, pathology, and nutrition specialists. Treatment sequencing is individualized based on tumor location, stage, histology, and patient-specific physiologic considerations.

As a fellowship-trained robotic surgical oncologist serving the San Francisco Bay Area, Dr. Geoffrey W. Krampitz provides surgical management of gastroesophageal junction tumors using evidence-based oncologic principles and advanced minimally invasive techniques when appropriate.

Understanding the Gastroesophageal Junction

The gastroesophageal junction is the anatomical transition where the distal esophagus meets the proximal stomach.

Tumors in this region often arise in the setting of:

  • chronic gastroesophageal reflux

  • Barrett’s esophagus

  • obesity and metabolic risk factors

Because the lymphatic drainage patterns and surgical anatomy differ between the esophagus and stomach, accurate classification of GEJ tumors is essential to treatment planning.

Siewert Classification of GEJ Tumors

GEJ tumors are commonly categorized using the Siewert classification, which describes tumor location relative to the gastroesophageal junction.

Siewert Type I
Tumors arising in the distal esophagus, typically associated with Barrett’s esophagus.

Siewert Type II
True junctional tumors centered at the gastroesophageal junction.

Siewert Type III
Tumors arising from the proximal stomach that extend into the junction.

This classification helps determine:

  • systemic therapy strategy

  • surgical approach

  • lymph node dissection patterns

Symptoms

Symptoms often develop as the tumor narrows the esophageal lumen or disrupts gastric function.

Common symptoms include:

  • progressive difficulty swallowing (dysphagia)

  • sensation of food sticking in the chest

  • unintentional weight loss

  • reflux symptoms

  • early satiety

  • anemia

Early-stage disease may produce minimal symptoms and may be discovered during evaluation for reflux or Barrett’s esophagus.

Staging and Pre-Treatment Evaluation

Accurate staging is critical to determine treatment strategy.

Evaluation typically includes:

  • CT scan of the chest, abdomen, and pelvis

  • PET scan to evaluate for distant metastases

  • Endoscopic ultrasound (EUS) for local staging

EUS is particularly valuable in assessing:

  • tumor depth

  • regional lymph node involvement

For many GEJ tumors—particularly those with gastric extension—diagnostic laparoscopy may be performed to detect occult peritoneal disease not visible on imaging.

Nutritional and Physiologic Optimization

Because dysphagia and reduced oral intake are common, early nutritional evaluation is essential.

In selected patients, enteral feeding access such as a jejunostomy tube may be placed prior to treatment to:

  • maintain nutritional status

  • support tolerance of systemic therapy

  • reduce treatment interruptions

  • optimize postoperative recovery

Patients being considered for surgery also undergo careful cardiopulmonary assessment to ensure physiologic readiness for major oncologic surgery.

Multimodality Treatment Strategy

Curative treatment for gastroesophageal junction tumors requires coordinated multimodality therapy integrating systemic treatment and surgery. Optimal treatment sequencing depends on tumor location, histologic subtype, stage, and patient physiology.

Because GEJ tumors arise at the interface between the esophagus and stomach, treatment strategies may draw from both esophageal cancer and gastric cancer treatment paradigms.

Historically, neoadjuvant chemoradiation followed by surgery—established by the CROSS Trial—defined the modern trimodality treatment approach for many esophageal and junctional cancers, particularly tumors with predominantly esophageal characteristics.

Subsequently, the FLOT4 Trial demonstrated improved outcomes with perioperative chemotherapy for gastric and gastroesophageal junction adenocarcinoma, establishing FLOT-based perioperative therapy as a standard strategy for many junctional tumors with greater gastric involvement.

More recently, advances in immunotherapy have further expanded treatment options. The CheckMate 577 showed improved disease-free survival with adjuvant immunotherapy following neoadjuvant chemoradiation and surgery in selected patients.

Contemporary studies such as the MATTERHORN Trial demonstrated the role of perioperative chemo-immunotherapy, reflecting a continued shift toward biologically tailored systemic treatment strategies.

As a result, modern management of GEJ tumors increasingly requires individualized multidisciplinary decision-making to determine whether chemoradiation-based or perioperative systemic therapy strategies are most appropriate.

In selected patients, biomarker testing—including HER2 status, PD-L1 expression, and mismatch repair status—may further inform systemic therapy selection and clinical trial eligibility.

Surgical Management

Surgery remains a cornerstone of curative treatment for localized GEJ tumors.

The operative strategy depends on tumor location and extent of esophageal involvement.

Possible surgical approaches include:

  • Esophagectomy with gastric conduit reconstruction

  • Extended total gastrectomy with distal esophageal resection

Both operations aim to achieve:

  • complete tumor removal with negative margins

  • adequate lymph node harvest

  • restoration of gastrointestinal continuity

Careful operative planning ensures appropriate lymphadenectomy patterns based on tumor location.

Robotic and Minimally Invasive Upper GI Surgery

Advances in minimally invasive and robotic surgery have refined operations for GEJ tumors.

Robotic platforms can enhance visualization and dexterity within the mediastinum and upper abdomen, allowing:

  • precise lymph node dissection

  • controlled mediastinal dissection

  • improved reconstruction in confined anatomical spaces

In experienced programs, minimally invasive approaches may support:

  • reduced wound complications

  • faster recovery

  • shorter hospital stays

However, operative approach is individualized based on tumor anatomy and patient safety. Oncologic integrity always takes precedence over technical modality.

Learn more about the broader surgical philosophy in the Robotic Surgery section.

Potential Risks After Surgery

Surgical treatment of GEJ tumors involves major upper gastrointestinal reconstruction.

Potential complications include:

  • pulmonary complications

  • anastomotic leak

  • delayed gastric emptying

  • cardiac rhythm disturbances

  • nutritional challenges during recovery

Early recognition and coordinated postoperative care are essential to minimize complications.

Recovery and Long-Term Follow-Up

Recovery varies depending on:

  • pre-treatment nutritional status

  • response to systemic therapy

  • extent of surgery

  • physiologic reserve

Long-term follow-up focuses on:

  • nutritional rehabilitation

  • surveillance for recurrence

  • management of reflux or swallowing symptoms

Multidisciplinary Care

Optimal management of GEJ tumors requires collaboration among multiple specialties.

Care typically involves:

  • surgical oncology

  • medical oncology

  • radiation oncology

  • gastroenterology

  • pulmonology and cardiology

  • nutrition specialists

  • radiology and pathology

Treatment decisions are individualized through multidisciplinary discussion to align tumor biology, staging, and patient goals.

Conclusion: Precision Multimodality Care for GEJ Tumors

Gastroesophageal junction tumors represent a unique interface between esophageal and gastric oncology. Successful treatment requires precise staging, thoughtful integration of systemic therapy, and technically sophisticated surgical management.

When delivered within experienced multidisciplinary programs, modern multimodality therapy—including minimally invasive surgery when appropriate—offers the best opportunity for durable disease control and meaningful recovery.

Consultation and Referral

For Patients:
Individuals seeking evaluation for gastroesophageal junction tumors may Request a Consultation to discuss individualized treatment strategies.

For Referring Physicians:
Physicians wishing to refer a patient or discuss complex upper gastrointestinal cancers may visit For Physicians for coordinated referral pathways and case review.